Trials / Unknown
UnknownNCT04255017
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Tongji Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abidol hydrochloride | Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I. |
| DRUG | Oseltamivir | Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I. |
| DRUG | Lopinavir/ritonavir | Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I. |
Timeline
- Start date
- 2020-02-01
- Primary completion
- 2020-06-01
- Completion
- 2020-07-01
- First posted
- 2020-02-05
- Last updated
- 2020-03-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04255017. Inclusion in this directory is not an endorsement.